EUVIMEDEUVIMED entdecken
Vergleichsstudie

Long‐Term Outcomes of Belatacept Versus Tacrolimus Following T‐Cell Depleting Induction in Adult Kidney Transplantation

Laura E Newton iD, Thomas W D'Angelo iD, Michael C Chobanian iD, Michael F Daily iD, Asha M Zimmerman iD

Clinical Transplantation · 2025-04 · 39 (4)

DOI: 10.1111/ctr.70154 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Transplantation, online erschienen am 15.04.2025. Verfasst von Laura E Newton und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Dartmouth Health, Lebanon, New Hampshire, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Tacrolimus, Abatacept, Graft Rejection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Veterans Health Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Belatacept shows promise as an alternative immunosuppressant without the nephrotoxicity of calcineurin inhibitors. Avoiding nephrotoxicity is important with the expanding use of organs at risk of marginal graft function. To date, no large studies have compared belatacept directly with tacrolimus after T‐cell depleting induction in renal transplantation.

Methods

The Standard Transplant Analysis and Research file was used to compare adult kidney transplant recipients induced with T‐cell depleting agents treated with belatacept to propensity score‐matched recipients treated with tacrolimus between August 10, 2011 and June 29, 2023. Kaplan–Meier survival analysis was used to compare death censored graft survival, patient survival, and time to acute rejection.

Results

During the study period, 4391 adult kidney transplant recipients were treated with belatacept. Estimated GFR improved for belatacept‐treated patients through year 9, whereas it decreased for the control group through year 10. Belatacept‐treated patients had a higher rejection rate at 5 years (21% vs. 15%, p < 0.001). Death‐censored graft survival did not differ between groups ( p = 0.383). Among patients who had rejection, death‐censored graft survival was superior in belatacept‐treated patients at 5 years (70% vs. 60%, p = 0.026). Overall, patient survival did not differ between groups ( p = 0.120).

Conclusions

This is the largest longitudinal study to compare outcomes of belatacept versus tacrolimus‐based therapy following T‐cell depleting induction. Belatacept was associated with improved graft function despite an increased acute rejection rate. There was no difference in overall graft or patient survival compared to tacrolimus. This study suggests that belatacept‐based therapy is not inferior to tacrolimus‐based therapy following T‐cell depletion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationTacrolimusAbataceptGraft RejectionImmunosuppressive AgentsT-LymphocytesKidney Failure, ChronicLymphocyte DepletionPostoperative ComplicationsHumansMaleFemaleGraft SurvivalMiddle AgedFollow-Up StudiesPrognosisAdultSurvival RateRetrospective StudiesGlomerular Filtration RateRisk Factors

Stichwörter der Autor:innen

belataceptimmunosuppressionkidneytacrolimus

Substanzen

TacrolimusAbataceptImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of General Surgery, Dartmouth Health, Lebanon, New Hampshire, USA.
  • Department of Surgery, Veterans Affairs Medical Center, White River Junction, Vermont, USA.
  • Tuck School of Business at Dartmouth, Hanover, New Hampshire, USA.
  • Department of Solid Organ Transplantation, Dartmouth Health, Lebanon, New Hampshire, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.

ORCID-Profile: Laura E Newton, Thomas W D'Angelo, Michael C Chobanian, Michael F Daily, Asha M Zimmerman

Förderung

  • Veterans Health Affairs

Zitieren

APA

Newton, L. E., D'Angelo, T. W., Chobanian, M. C., Daily, M. F., & Zimmerman, A. M. (2025). Long‐Term Outcomes of Belatacept Versus Tacrolimus Following T‐Cell Depleting Induction in Adult Kidney Transplantation. Clinical Transplantation, 39(4). https://doi.org/10.1111/ctr.70154

Vancouver

Newton LE, D'Angelo TW, Chobanian MC, Daily MF, Zimmerman AM. Long‐Term Outcomes of Belatacept Versus Tacrolimus Following T‐Cell Depleting Induction in Adult Kidney Transplantation. Clinical Transplantation. 2025;39(4). doi:10.1111/ctr.70154

BibTeX
@article{Newton2025,
  author = {Newton, Laura E and D'Angelo, Thomas W and Chobanian, Michael C and Daily, Michael F and Zimmerman, Asha M},
  title = {Long‐Term Outcomes of Belatacept Versus Tacrolimus Following T‐Cell Depleting Induction in Adult Kidney Transplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  volume = {39},
  number = {4},
  doi = {10.1111/ctr.70154}
}
Kostenlos starten →